R P Dellinger. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Adjuvants, Immunologic/therapeutic useAntibodies, Monoclonal/therapeutic useClinical Trials, Phase II as TopicData Interpretation, StatisticalHumansImmunoglobulin Fab Fragments/therapeutic useProspective StudiesSepsis/mortalitySepsis/therapyTreatment OutcomeTumor Necrosis Factor-alpha/immunology
Substances: See more » Adjuvants, ImmunologicAntibodies, MonoclonalImmunoglobulin Fab FragmentsTumor Necrosis Factor-alpha
Year: 1996 PMID: 8706445 DOI: 10.1097/00003246-199605000-00001
Source DB: PubMed Journal: Crit Care Med ISSN: 0090-3493 Impact factor: 7.598